Benzinga's Top #PreMarket Gainers

shares rose 53.45 percent to $6.00 in pre-market trading after the company reported positive top-line results from METEOR, Phase 3 pivotal trial of Cabozantinib vs. Everolimus in patients with metastatic renal cell carcinoma.

gained 6.53 percent to $39.50 in pre-market trading after the company issued a strong Q2 sales forecast.

shares rose 3.25 percent to $41.29 in pre-market trading after the company reported stronger-than-expected results for its second quarter.

shares climbed 3.07 percent to $41.00 in pre-market trading. Bank of America initiated coverage on Cellectis with a Buy rating and a $50.00 price target.

shares climbed 3.03 percent to $41.42 in pre-market trading after the company reported upbeat earnings for the second quarter.